Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Stake Lessened by Principal Financial Group Inc.

Principal Financial Group Inc. decreased its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 43.5% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,594 shares of the biopharmaceutical company’s stock after selling 5,837 shares during the period. Principal Financial Group Inc.’s holdings in Agios Pharmaceuticals were worth $327,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Quest Partners LLC bought a new stake in shares of Agios Pharmaceuticals in the 4th quarter worth $41,000. NEOS Investment Management LLC bought a new stake in Agios Pharmaceuticals in the fourth quarter worth about $210,000. Northcape Wealth Management LLC acquired a new stake in Agios Pharmaceuticals in the 2nd quarter valued at about $244,000. Entropy Technologies LP bought a new position in shares of Agios Pharmaceuticals during the 1st quarter valued at about $286,000. Finally, China Universal Asset Management Co. Ltd. grew its stake in shares of Agios Pharmaceuticals by 66.6% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 10,780 shares of the biopharmaceutical company’s stock worth $315,000 after purchasing an additional 4,311 shares during the last quarter.

Insider Activity

In other news, CEO Brian Goff sold 11,091 shares of the stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $42.75, for a total value of $474,140.25. Following the completion of the sale, the chief executive officer now directly owns 78,792 shares of the company’s stock, valued at $3,368,358. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 4.93% of the stock is owned by corporate insiders.

Agios Pharmaceuticals Stock Performance

NASDAQ AGIO opened at $46.69 on Friday. The firm’s 50 day moving average price is $45.45 and its two-hundred day moving average price is $38.71. The stock has a market cap of $2.66 billion, a price-to-earnings ratio of -7.39 and a beta of 0.75. Agios Pharmaceuticals, Inc. has a twelve month low of $19.80 and a twelve month high of $50.35.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.60) by ($0.09). The business had revenue of $8.60 million for the quarter, compared to analysts’ expectations of $9.34 million. Agios Pharmaceuticals had a negative net margin of 1,165.69% and a negative return on equity of 47.05%. The business’s quarterly revenue was up 28.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.51) EPS. On average, research analysts forecast that Agios Pharmaceuticals, Inc. will post -4.85 EPS for the current fiscal year.

Analysts Set New Price Targets

AGIO has been the subject of several recent research reports. Royal Bank of Canada increased their target price on shares of Agios Pharmaceuticals from $53.00 to $55.00 and gave the company an “outperform” rating in a research note on Friday, August 2nd. Cantor Fitzgerald reiterated an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Monday, June 17th. StockNews.com cut Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, August 5th. The Goldman Sachs Group upped their target price on Agios Pharmaceuticals from $33.00 to $53.00 and gave the company a “neutral” rating in a report on Tuesday, June 4th. Finally, JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $46.00 price target on shares of Agios Pharmaceuticals in a research report on Thursday, June 13th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $51.33.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.